Current Headlines

  1. Minerva Biotechnologies Granted Worldwide License To iPS Technology
    8/4/2015

    Minerva Biotechnologies and iPS Academia Japan, Inc. announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Professor Shinya Yamanaka, MD, Ph.D., who won the Nobel Prize for Medicine in 2012 for his discovery of four genes that can reprogram an adult’s cell to go back in time to become that person’s own stem cell

  2. AmpliPhi BioSciences Cleared To Submit Listing Application To NYSE MKT
    8/4/2015

    AmpliPhi BioSciences Corporation, a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, recently announced that its board of directors has approved a one-for-fifty reverse split of the company’s common stock to become effective at market open on August 07, 2015

  3. Catabasis Pharmaceuticals To Present At The Wedbush PacGrow Healthcare Conference
    8/4/2015

    Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced that Catabasis will present a company overview at the Wedbush PacGrow Healthcare Conference

  4. NYSCF Global Stem Cell Array Brings Precision Medicine One Step Closer To The Clinic
    8/3/2015

    Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute successfully designed a revolutionary, high-throughput, robotic platform that automates and standardizes the process of transforming patient samples into stem cells

  5. Contextual Genomics And The Personalized Medicine Initiative Add ArcherDX, The Sixth Consortium Partner, To Its National Access Project
    8/3/2015

    Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, are pleased to welcome its sixth consortium partner, ArcherDX, to the National Access Project

  6. Pfizer And Synthon Enter Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis
    8/3/2015

    Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, recently announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS)

  7. Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy
    8/3/2015

    Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development, announced the formation of its tenth consortium: The Duchenne Regulatory Sciences Consortium (D-RSC).

  8. AstraZeneca And Isis Pharmaceuticals To Discover And Develop Antisense Drugs For Cardiovascular, Metabolic And Renal Diseases
    8/3/2015

    Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.

  9. Michigan-Focused Academic Drug Discovery, Development Symposium Presented By MichBio And The University Research Corridor
    7/29/2015

    Michigan’s first event to showcase the state’s academic drug R&D activities will be held on September 9-10, 2015 and hosted by Michigan State University

  10. Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
    7/29/2015

    Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, recently announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has initiated enrolment in a pivotal study to assess the safety and efficacy of HLD-200 – a next-generation formulation of methylphenidate – in children with Attention-Deficit/Hyperactivity Disorder (“ADHD”)

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.